CADL: Multiplikator P/S Candel

Candel Therapeutics focuses on viral immunotherapy for brain and prostate tumors, relying on payments from government funds and insurers. The company's current P/S ratio reflects the market valuation of its capitalization relative to revenue, with the level sitting around 1523.70. This price action is linked to the transition to Phase III trials and a high dependency on external contract manufacturing organizations for drug production.

To identify fundamentally resilient assets, investors evaluate the price-to-sales ratio, which determines the extent to which a business is overvalued relative to its current revenue. Since Candel Therapeutics (CADL) has no commercial products, this P/S volatility reflects speculative expectations from clinical trials rather than the company's actual pricing power in the cancer drug market.